Fig. 1 · Structure

Documents & Downloads

Naringin (Naringoside)

Cat. No. A10626 CAS 10236-47-2
Naringin (Naringoside) is a flavanone glycoside and is a major flavonoid in grapefruit and gives the grapefruit juice its bitter taste.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
P450

Cellular Effect

Cell Line Activity Value Description Reference
Monocyte IC50 > 200 μM Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA [PMID: 10096854]
Oocyte EC50 > 100 μM Activation of recombinant human GIRK1/4 expressed in Xenopus oocytes by two-electrode voltage clamp method [PMID: 23916258]
Oocyte EC50 > 100 μM Activation of recombinant human GIRK1/2 expressed in Xenopus oocytes by two-electrode voltage clamp method [PMID: 23916258]

Naringin (Naringoside) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Naringin (Naringoside) from 2 published references. In vitro models include RA-FLS.

Naringin (Naringoside) In Vitro Studies

Naringin at 80 μg/ml significantly decreased RA-FLS viability in a time-dependent manner. Incubation of RA-FLS with various concentrations of Naringin also gradually increased the percentage of apoptotic cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Naringin decreases RA-FLS viability

Cell-based study · RA-FLS [1]

RA-FLS exposed to Naringin at 80 μg/ml showed a significant, time-dependent decrease in cell viability.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was measured using CCK-8 assay.Reported result treatment of RA-FLS with 80 μg/ml naringin significantly decreased cell viability (p < 0.05) in a time-dependent manner[1]

Literature-Reported Treatment Conditions

Treatment concentration
80 μg/ml
Exposure duration
24–72 h
Method
exposed to naringin
Vehicle
DMSO
Reported limits
Not stated in the sentences used: control.
Methods and source locations

Compound reported in the paper: Naringin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Chemical Reagents (S1); Materials and Methods > Cell Viability Assay (S41, S43, S44); Results > Naringin Decreases Cell Viability of RA-FLS (S95, S96)

Cell viability was measured using CCK-8 assay.: Cell viability was measured using CCK-8 assay. — Materials and Methods > Cell Viability Assay (S41); Results > Naringin Decreases Cell Viability of RA-FLS (S96)

Naringin increases the percentage of apoptotic RA-FLS

Cell-based study · RA-FLS [1]

RA-FLS were incubated with various concentrations of Naringin. The percentage of apoptotic cells gradually increased.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage of apoptotic cellsReported result After incubating in various concentrations of naringin, the percentage of apoptotic cells was found to be gradually increased (p < 0.05)[1]

Literature-Reported Treatment Conditions

Method
incubating in various concentrations of naringin
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, schedule, control.
Methods and source locations

Compound reported in the paper: Naringin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Chemical Reagents (S1); Materials and Methods > Flow Cytometric Analysis of Apoptosis (S67); Results > Naringin Enhances Apoptosis of RA-FLS (S98, S99)

percentage of apoptotic cells: percentage of apoptotic cells — Results > Naringin Enhances Apoptosis of RA-FLS (S99)

Naringin (Naringoside) In Vivo Studies

Male Wistar rats with colitis received Naringin orally at 40 and 80 mg/kg for 12 days. Naringin significantly and dose dependently decreased ulcer area compared with acetic acid control rats. [2]

Naringin reduces ulcer area in rats with colitis

Animal study · Male wistar rats (180-200 g); Colitis; n = 6/group [2]

Male Wistar rats with colitis received Naringin orally at 40 and 80 mg/kg for 12 days. Ulcer area decreased significantly and dose dependently compared with acetic acid control rats.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ulcer area (mm2)Ulcer area 40 mg/kg: 19.99±1.63 mm2; 80 mg/kg: 13.02±0.79 mm2[2]

Conditions shared by the study groups

Route
p.o.
Treatment course
for 12 days and 2 mL 4% acetic acid intra-rectally on the 8th day
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Naringin 40 and 80 mg/kg2 mL 4% acetic acid (once, intra-rectally) and 1 mL distilled water for 12 days40 mg/kg: 19.99±1.63 mm2; 80 mg/kg: 13.02±0.79 mm2; significantly (P < 0.05) and dose dependently (40 and 80 mg/kg) decreased ulcer area as compared to acetic acid control rats[2]
Naringin 40 and 80 mg/kg
Model: Male wistar rats (180-200 g); Colitis; n = 6/group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Naringin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIAL AND METHODS > Animals (S1); MATERIAL AND METHODS > Induction of colitis (S16, S17); RESULTS > Naringin attenuated acetic acid-induced colitis (S60); Table 1 (T1.h1, T1.r5, T1.r6)

Ulcer area (mm2): Ulcer area (mm2); comparator: 2 mL 4% acetic acid (once, intra-rectally) and 1 mL distilled water for 12 days — RESULTS > Naringin attenuated acetic acid-induced colitis (S60); Table 1 (T1.h1, T1.r5, T1.r6)

Naringin 40 and 80 mg/kg · MATERIAL AND METHODS > Induction of colitis (S17); RESULTS > Naringin attenuated acetic acid-induced colitis (S60); Table 1 (T1.h1, T1.r5, T1.r6)

Specifications

Manufacturer Adooq Bioscience
CAS Number 10236-47-2
Formula C27H32O14
Molecular Weight 580.5
Synonyms Naringenine-7-rhamnosidoglucoside; Naringoside
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 93 mg/mL (160.19 mM)
Water Insoluble
Ethanol 2 mg/mL (3.44 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Naringin (Naringoside) Research References

  1. [1] Aihaiti Y, Song Cai Y, Tuerhong X, et al. Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation. Front Pharmacol (2021). PMID: 34054546 DOI: 10.3389/fphar.2021.672054 Source material
  2. [2] Kumar VS, Rajmane AR, Adil M, et al. Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats. J Biomed Res (2014). PMID: 24683411 DOI: 10.7555/JBR.27.20120082 Source material

Added to your cart

View Cart Checkout
Loading...